A phase II study of bevacizumab in non-squamous, non-small-cell lung cancer patients with malignant pleural effusion
Wu Di, Cong Yue, Zhang Ziran, Zhang Jie, Nie Jun, Dai Ling, Hu Weiheng, Chen Xiaoling, Ma Xiangjuan, Tian Guangming, Han Jindi, Han Sen, Wang Yang, Long Jieran, Fang Jian, Wu Di, Cong Yue, Zhang Ziran, Zhang Jie, Nie Jun, Dai Ling, Hu Weiheng, Chen Xiaoling, Ma Xiangjuan, Tian Guangming, Han Jindi, Han Sen, Wang Yang, Long Jieran, Fang Jian
Abstract
Aim: To investigate the efficacy, safety and optimal dosage of bevacizumab in non-squamous, non-small-cell lung cancer (NSCLC) patients with malignant pleural effusion (MPE). Methods: 20 patients were enrolled and received intrapleural injection of bevacizumab (group A: 2.5 mg/kg d1, d8; group B: 5 mg/kg d1, d8; group C: 7.5 mg/kg d1, d8). Results: The objective response rate (ORR) of MPE was 50%. The median progression-free survival (PFS) of MPE was 7.0 months (95% CI 4.9-9.2). The ORR and PFS of MPE from group B were better than those of group A and group C. The most common adverse events (AEs) were hypertension (15%) and anemia (15%). Conclusion: Bevacizumab has certain efficacy in non-squamous NSCLC patients with MPE. Clinical Trial Registration: NCT02942043 (ClinicalTrials.gov).
Keywords: bevacizumab; malignant pleural effusion; non-small-cell lung cancer; phase II.
Source: PubMed